Rajesh S Mony
Mast cell degranulation mediated by various allergen with subsequent cross linking of Antigen Antibody complex is the chief triggering mechanism of allergic inflammatory response. Among many mediators released, β-hexosaminidase have a leading role in propagating allergic reactions. The pharmacologic inhibition of this process would, therefore, have clear therapeutic potential. Luteolin formulations, alone or together with drugs that can selectively inhibit the release of pro-inflammatory mediators hold promise for the treatment of skin and brain inflammatory diseases. In this work, antiallergic properties particularly the inhibition of mast cell degranulation was studied with two of the samples A and B. Inhibition of β-hexosaminidase release by the samples have been studied.
Pages: 698-701 | 433 Views 186 Downloads